Jozef Šufliarský

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study

Marie‐Françoise Avril, Steinar Aamdal, Jean‐Jacques Grob et al. · Journal of Clinical Oncology · 2004 · 470 citations

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial

Patrick Schöffski, Jozef Šufliarský, Hans Gelderblom et al. · The Lancet Respiratory Medicine · 2018 · 176 citations

Lymphoid Neoplasia, European Organisation, Medicine +9

<i>KIT</i> and <i>PDGFRA</i> Mutations and the Risk of GI Stromal Tumor Recurrence

Heikki Joensuu, Piotr Rutkowski, Toshirou Nishida et al. · Journal of Clinical Oncology · 2015 · 172 citations · Full text

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Patrick Schöffski, Agnieszka Woźniak, Bernard Escudier et al. · European Journal of Cancer · 2017 · 114 citations

Urology, Eortc 90101, Genitourinary Cancer +9